TY - JOUR
T1 - The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies
AU - Li, Jia Ling
AU - Shen, Guo Liang
AU - Ghetie, Maria Ana
AU - May, Richard D.
AU - Till, Mark
AU - Ghetie, Victor
AU - Uhr, Jonathan W.
AU - Janossy, George
AU - Thorpe, Philip E.
AU - Amlot, Peter
AU - Vitetta, Ellen S.
N1 - Funding Information:
’ This work is supported in part by NIH Grants AI-1185 1, CA-28 149, and CA-4 IO8 1 and a grant from the Welch Foundation, I-0947. ’ Abbreviations used: BSS, balanced salt solution; CLL, chronic lymphocytic leukemia; dgA, deglycosy-lated ricin A chain; FITC, lluorescein isothiocyanate; GAMIg, goat anti-mouse immunoglobulin; HAT, hypoxanthine/aminopterin/thymid.ine; Ig, immunoglobulin; ITS, immunotoxins; 2-ME, 2-mercaptoethanol; MFI, mean 8uorescenc.e intensity; MoAb, monoclonal antibody; PBS, phosphate-buffered saline; BAMIg, rabbit anti-mouse Ig; BIA, radioimmunoassay; SDS-PAGE, sodium dodecyl suIfate-polyacrylamide gel electrophoresis; SN, supematant.
PY - 1989/1
Y1 - 1989/1
N2 - The CD22 antigen is expressed on the surface of normal human B cells and some neoplastic B cell lines and tumors. Previous cross-blocking studies using a panel of monoclonal anti-CD22 antibodies have defined four epitope groups, termed A-D. In the present studies, we have further dissected the epitopes recognized by four monoclonal anti-CD22 antibodies using immunopre-cipitation and cross-blocking techniques, immunofluorescence analyses with a variety of cell lines, and immunoperoxidase analyses of 36 normal human tissues. Two of the antibodies, HD6 and RFB4, have been described previously, and two, UV22-1 and UV22-2, are described in this report. Our studies indicate that the four monoclonal antibodies show unexpected complexities in their reactivity with CD22+ and CD22- cells and their reactivity with solubilized CD22 molecules. The four antibodies, which recognize epitopes defined previously as CD22-A and CD22-B, further subdivide these epitope clusters into four determinants, A1, A2, B1, and B2. Furthermore, only two of the antibodies, RFB4 and UV22-2, are B cell-specific. In summary, our data indicate that RFB4 and UV22-2 would be the antibodies of choice for constructing immunotoxins to treat B cell tumors.
AB - The CD22 antigen is expressed on the surface of normal human B cells and some neoplastic B cell lines and tumors. Previous cross-blocking studies using a panel of monoclonal anti-CD22 antibodies have defined four epitope groups, termed A-D. In the present studies, we have further dissected the epitopes recognized by four monoclonal anti-CD22 antibodies using immunopre-cipitation and cross-blocking techniques, immunofluorescence analyses with a variety of cell lines, and immunoperoxidase analyses of 36 normal human tissues. Two of the antibodies, HD6 and RFB4, have been described previously, and two, UV22-1 and UV22-2, are described in this report. Our studies indicate that the four monoclonal antibodies show unexpected complexities in their reactivity with CD22+ and CD22- cells and their reactivity with solubilized CD22 molecules. The four antibodies, which recognize epitopes defined previously as CD22-A and CD22-B, further subdivide these epitope clusters into four determinants, A1, A2, B1, and B2. Furthermore, only two of the antibodies, RFB4 and UV22-2, are B cell-specific. In summary, our data indicate that RFB4 and UV22-2 would be the antibodies of choice for constructing immunotoxins to treat B cell tumors.
UR - http://www.scopus.com/inward/record.url?scp=0024536868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024536868&partnerID=8YFLogxK
U2 - 10.1016/0008-8749(89)90359-6
DO - 10.1016/0008-8749(89)90359-6
M3 - Article
C2 - 2463099
AN - SCOPUS:0024536868
SN - 0008-8749
VL - 118
SP - 85
EP - 99
JO - Cellular Immunology
JF - Cellular Immunology
IS - 1
ER -